Does Rallies show 13F holders for CORT?

Yes. Rallies tracks hedge fund and 13F ownership data for CORT, including fund names, share counts, latest tracked quarter, and position changes when available.

Is CORT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CORT. It does not provide personalized investment advice.

CORT (Corcept Therapeutics Inc.) Stock Analysis - Hedge Fund Holdings

Corcept Therapeutics Inc. (CORT) is a publicly traded Healthcare sector company. As of May 21, 2026, CORT trades at $59.39 with a market cap of $5.92B and a P/E ratio of 58.52. CORT moved +1.58% today. Year to date, CORT is +68.98%; over the trailing twelve months it is -22.51%. Its 52-week range spans $28.66 to $117.33. Analyst consensus is strong buy with an average price target of $86.25. Rallies surfaces CORT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns CORT stock?

Hedge funds tracked by Rallies that own CORT include Bridgewater Associates, Polen Capital, Mangrove Partners, and Pinebridge Investments. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Corcept Therapeutics Inc..

CORT Key Metrics

Key financial metrics for CORT
Metric	Value
Price	$59.39
Market Cap	$5.92B
P/E Ratio	58.52
EPS	$1.00
Dividend Yield	0.00%
52-Week High	$117.33
52-Week Low	$28.66
Volume	1
Avg Volume	0
Revenue (TTM)	$741.17M
Net Income	$106.11M
Gross Margin	98.19%

Top Hedge Funds Holding CORT

Bridgewater Associates holds 38.42K shares of CORT, changed -86.23% as of Mar 31, 2026.
Polen Capital holds 28.36K shares of CORT, changed +31.46% as of Sep 30, 2025.
Mangrove Partners holds 9.50K shares of CORT, changed +0.00% as of Jun 30, 2025.
Pinebridge Investments holds 1.38K shares of CORT, changed +0.00% as of Jun 30, 2023.

Latest CORT News

Corcept climbs as DAZALS two-year ALS survival data revives pipeline momentum — May 6, 2026
Corcept climbs as 2026 revenue outlook jumps and Lifyorli launch momentum builds — May 1, 2026
Corcept to Present Phase 3 Platinum-Resistant Ovarian Cancer Survival Data May 29 — Apr 21, 2026
Corcept’s Lifyorli Gains Early FDA Approval, Driving 18.5% Stock Jump — Mar 26, 2026
Corcept Therapeutics Q4 Revenue Climb Bolstered by Korlym, Pipeline Costs Rise — Feb 25, 2026

Recent CORT Insider Trades

Guyer William sold 20.00K (~$1.04M) on May 5, 2026.
BELANOFF JOSEPH K sold 40.00K (~$2.00M) on May 1, 2026.
Guyer William sold 20.00K (~$819.40K) on Apr 7, 2026.

CORT Analyst Consensus

6 analysts cover CORT: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $86.25.

Common questions about CORT

Who owns CORT stock?: Hedge funds tracked by Rallies that own CORT include Bridgewater Associates, Polen Capital, Mangrove Partners, and Pinebridge Investments. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Corcept Therapeutics Inc..
Does Rallies show 13F holders for CORT?: Yes. Rallies tracks hedge fund and 13F ownership data for CORT, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CORT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CORT. It does not provide personalized investment advice.